Letermovir

Letermovir (AIC246) is a potent inhibitor of CMV, which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors.

Product Specifications

CAS Number

[917389-32-3]

Product Name Alternative

AIC246; MK-8228

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

CMV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/letermovir.html

Purity

99.96

Solubility

DMSO : ≥ 100 mg/mL

Smiles

FC1=C(N=C(N2CCN(C3=CC=CC(OC)=C3)CC2)N(C4=CC(C(F)(F)F)=CC=C4OC)[C@H]5CC(O)=O)C5=CC=C1

Molecular Formula

C29H28F4N4O4

Molecular Weight

572.55

Precautions

H302, H312, H332

References & Citations

[1]Marschall M, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56 (2) :1135-7.|[2]Goldner T, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85 (20) :10884-93.|[3]Lischka P, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010 Mar;54 (3) :1290-7.|[4]Wildum S, et al. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59 (6) :3140-8.